

Brucellosis Unusually Presented as Septic Knee Arthritis: A Case Report

Bassem Alhariri¹, Mohammed Zuhair¹, and Abdulqadir Nashwan¹

¹Hamad Medical Corporation

August 15, 2022

Abstract

Brucellosis is one of the world's most prevalent zoonotic illnesses. The most often afflicted joints are the sacroiliac joints, although spondylitis and peripheral arthritis are becoming increasingly prevalent. We described a case of a 40-year-old male with Brucellosis presented as septic knee arthritis.

Brucellosis Unusually Presented as Septic Knee Arthritis: A Case Report

Bassem Al Hariri¹, Mohammed Zuhair¹, Abdulqadir J. Nashwan^{2*}

1. Internal Medicine Department, Hazm Mebaireek General Hospital, Hamad Medical Corporation, Doha, Qatar

Nursing Department, Hazm Mebaireek General Hospital, Hamad Medical Corporation, Doha, Qatar

*Corresponding author:

Mr. Abdulqadir J. Nashwan

anashwan@hamad.qa

Tel: (+974) 40240487

Mob: (+974) 66473549

P.O. Box 3050

Hamad Medical Corporation, Doha, Qatar

Informed Consent

Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.

ABSTRACT

Brucellosis is one of the world's most prevalent zoonotic illnesses. The most often afflicted joints are the sacroiliac joints, although spondylitis and peripheral arthritis are becoming increasingly prevalent. We described a case of a 40-year-old male with Brucellosis presented as septic knee arthritis.

Key Clinical Message

All patients with septic arthritis who reside in endemic areas should be screened for Brucellosis as appropriate.

Keywords: Brucellosis; Brucella melitensis; knee septic arthritis; osteoarticular involvement

INTRODUCTION

Brucellosis is one of the world's most prevalent zoonotic illnesses.(1, 2) Illness has struck the East Mediterranean region (EMRO).(3) A frequent brucellosis sign is osteoarticular involvement. The most often afflicted joints are the sacroiliac joints, although spondylitis and peripheral arthritis are becoming increasingly prevalent. Brucellosis is highly vulnerable to being ignored in the presence of companion bacteria.(3) As a consequence, it should be considered in all individuals with septic arthritis who reside or travel through endemic areas.

CASE PRESENTATION

A 40-year-old male with no prior medical history was hospitalized for 7 days due to (R) knee pain and swelling. Fever has been around for the past two weeks, coming and going. The discomfort made it impossible for him to walk. There were no gastrointestinal or genitourinary symptoms. As well as unremarkable cardiopulmonary and neurological review. No other joint involvement. No skin rashes and There was no history of trauma. The patient stated that he had a similar episode of knee pain 10 years ago. He denied any contact with animals and no history of raw milk consumption. His temperature was 37.8°C. The (R) knee was swollen, hot, and tender with a limited range of movement (Figure1). The deferential diagnosis included septic arthritis and crystal-induced arthritis. The general examination was normal. Laboratory investigation showed White Blood Count (WBC) of 5.2 and C-Reactive Protein (CRP) was high 110. Hemoglobin (Hb) was 12.9, mean corpuscular volume (MCV) 60.9; red blood cell distribution width (RDW) was 18.6, suggestive of iron deficiency anemia. Platelets were normal at 270. The coagulation profile showed high Prothrombin Time (PT) 12.8, international normalized ratio (INR), and partial thromboplastin time (PTT) were normal. Blood chemistry investigations were all normal. Brucella serology was done, which showed Brucella IgG was positive 1: 320, and IgM was negative. Synovial fluid aspirate revealed yellow, turbid fluid with WBCs of 4,800, red blood cells (RBCs) 13,475, neutrophils 31.0, lymphocytes 2.0, and monocytes 67. *Brucella melitensis* was detected in both blood cultures and synovial fluid. The echocardiogram did not reveal vegetation. Right knee soft tissue ultrasound revealed large joint effusion reaching suprapatellar bursa associated with synovial irregular thickening and hypervascularity (Figure 2). The largest collection measuring 8.1x2.2 cm. Rifampicin, doxycycline, and gentamycin were started, and his condition has improved.

DISCUSSION

One of the most widespread zoonotic diseases is brucellosis.(4) Dairy (unpasteurized) products, diseased animals' close contact, or the products of an animal's conception can all lead to infection. Rare instances of mother-to-child transmission of brucellosis during pregnancy and breastfeeding have been documented.(5) Because of its high infectivity by inhalation, brucellosis has the potential to be used as a biological weapon.(6)

Infections with *B. melitensis* continue to be an urgent public health concern in Mediterranean nations, southern, central, and western Asia, as well as certain portions of South and Central America, and many African countries. More than 100/100,000 person-years have been documented in the Middle East region, including Jordan, Iraq, and KSA.(7, 8) Despite appearing to be on the decline in some regions of Saudi Arabia, brucellosis is nevertheless an endemic disease, with prevalence peaking in those between the ages of 40 and 49.(9)

Brucellosis patients frequently experience a variety of symptoms, including splenomegaly, arthralgia, high fever, and malodorous perspiration. In some situations, the onset may be gradual or there may be a predominance of one organ over others (focal brucellosis). One of the brucellosis symptoms that occurs most frequently is osteoarticular involvement. There have been reports of peripheral arthritis, spondylitis, sacroiliitis, bursitis, and osteomyelitis among other conditions. The wrist and ankle tendons are the most frequently affected, and tenosynovitis comparable to the first documented case in 1908.(10) In a relatively recent meta-analysis, 26% of the infected individuals had arthritis, compared to 65% of patients with arthralgia. Spondylitis and sacroiliitis were seen in 12 to 36% of individuals overall.(11)

Especially in nonendemic locations, brucella arthritis diagnosis might be difficult. In endemic locations,

serology—often in conjunction with conventional agglutination tests (SAT) is the mainstay of diagnosis.(8) Blood cultures often require a long incubation period and have variable sensitivity ranging from 53% to 90%. Blood cultures may come back negative when the disease is limited to a single joint, so serology continues to serve as the foundation for laboratory diagnosis. Despite negative blood cultures, synovial fluid cultures can nonetheless be positive.

Blood culture sensitivity has increased with the use of automated systems, reaching up to 95%, while incubation times have decreased to just 7 days, (93.3%, 14/15) BACTEC cultures, (75.0%, 6/8) isolator cultures, and (57.1%, 4/7) conventional cultures all supported *B. melitensis* growth.(12) Leukocyte counts in synovial fluid analysis often show an exudative process with values between a few hundred and a few thousand.(2)

Although the two can occasionally coexist, synovial fluid analysis aids in differentiating crystal arthropathy from viral arthritis.(13) Although these approaches have decreased incubation, a faster and more accurate analysis is still required. Compared to conventional methods, PCR has demonstrated great sensitivity and specificity, enabling quicker and more accurate identification of the *Brucella*. However, because of issues with standards, its use is still infrequent.(14) Recent study has shown that MALDI-TOF MS is a simple, rapid, and highly accurate approach for identifying *brucella*.(15)

Because monotherapy is associated with significant recurrence rates, a two-drug combination is used. When compared to combination treatment, monotherapy had more than double the probability of overall failure (relative risk, 2.56).(16) The recommended course of treatment includes doxycycline 100 mg twice daily for six weeks and injectable streptomycin 0.75–1 gm once a day for a maximum of 3 weeks. In cases of serious brucellosis, triple therapy for a course lasting longer than 3 months is advised. With a shorter period of fewer than six weeks, both treatment failure (3.02, 1.03-8.80) and relapse (1.70, 1.19-2.44) were substantially more frequent. Contrarily, the aminoglycoside/doxycycline combination had a lower relapse rate than the combination of rifampicin and doxycycline, especially in cases of osteoarticular disease.(16)

According to a meta-analysis, 5-7% of patients treated with doxycycline-streptomycin and 11-17% with doxycycline-rifampin experienced treatment failure or relapse.(8) The simultaneous administration of rifampicin and doxycycline may have lowered the blood level of the drug, which could be one explanation.(7) Rifampicin resistance was not proven by molecular detection techniques or in vitro susceptibility tests. Overall, this low success rate is more likely attributable to poor compliance or a lack of time than to rifampicin resistance. Except for co-trimoxazole, other drugs' minimum inhibitory concentrations remain reassuringly low. Notably, avoiding rifampicin will eliminate the possibility of inducing resistance in tuberculosis in regions where TB and brucellosis are both widespread, particularly when TB is misdiagnosed as the underlying cause.

Compared to septic arthritis brought on by pyogenic organisms, *B. melitensis* patients experience modest joint inflammation, and erythema of the overlying skin is rare.(10) Having said that, making a clinical diagnosis based solely on local inflammatory symptoms may be challenging. The most common sign of brucellosis that should notify a doctor is a fever, which is typically undulant.

CONCLUSION

Brucellosis is still a difficult disease in endemic regions. Its many rheumatologic symptoms may be mistaken for various forms of arthritis. In non-endemic locations, extensive travel and contact histories are required to make an early diagnosis. In such circumstances, blood, synovial cultures, and brucellosis serology should be performed. Antibiotics combos and a lengthy duration of therapy are required to avoid *brucella* septic arthritis failure or recurrence.

Declarations

Ethics approval and consent to participate

The article describes a case report. Therefore, no additional permission from our Ethics Committee was

required.

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was not funded.

Authors' contributions

BAH, MZ, AJN: Data Collection, Literature Search, Manuscript Preparation

All authors read and approved the final manuscript

Acknowledgments

Open Access funding provided by the Qatar National Library.

REFERENCES

1. Amro A, Mansoor B, Hamarsheh O, Hjaija D. Recent trends in human brucellosis in the West Bank, Palestine. *International Journal of Infectious Diseases*. 2021;106:308-13.
2. Lim HS, Song YG, Yoo HS, Park MY, Kim JW. Brucellosis: an overview. *Korean Journal of Epidemiology*. 2005;27(1):26-36.
3. Elzein FE, Sherbeeni N. Brucella septic arthritis: case reports and review of the literature. *Case Reports in Infectious Diseases*. 2016;2016.
4. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. *The Lancet infectious diseases*. 2006;6(2):91-9.
5. Aydın B, Beken S, Akansel R, Dilli D, Okumuş N, Zenciroğlu A, et al. Prematurity due to maternal brucella infection and review of the literature. *Turk J Pediatr*. 2013;55(4):433-7.
6. Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P, Bronze MS. Bacterial pathogens as biological weapons and agents of bioterrorism. *The American journal of the medical sciences*. 2002;323(6):299-315.
7. Corbel MJ. Brucellosis: an overview. *Emerging infectious diseases*. 1997;3(2):213.
8. Rubach MP, Halliday JE, Cleaveland S, Crump JA. Brucellosis in low-income and middle-income countries. *Current opinion in infectious diseases*. 2013;26(5):404.
9. Al-Tawfiq JA, AbuKhamis A. A 24-year study of the epidemiology of human brucellosis in a health-care system in Eastern Saudi Arabia. *Journal of infection and public health*. 2009;2(2):81-5.
10. Madkour MM. *Madkour's brucellosis*: Springer Science & Business Media; 2012.
11. Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. *PLoS neglected tropical diseases*. 2012;6(12):e1929.
12. Yagupsky P. Detection of Brucellae in blood cultures. *Journal of clinical microbiology*. 1999;37(11):3437-42.
13. Yu K, Luo S, Liou L, Wu YJ, Tsai W, Chen J, et al. Concomitant septic and gouty arthritis—an analysis of 30 cases. *Rheumatology*. 2003;42(9):1062-6.

14. Wang Y, Wang Z, Zhang Y, Bai L, Zhao Y, Liu C, et al. Polymerase chain reaction–based assays for the diagnosis of human brucellosis. *Annals of clinical microbiology and antimicrobials*. 2014;13(1):1-8.
15. Ferreira L, Vega Castaño S, Sánchez-Juanes F, González-Cabrero S, Menegotto F, Orduña-Domingo A, et al. Identification of *Brucella* by MALDI-TOF mass spectrometry. Fast and reliable identification from agar plates and blood cultures. *PLoS One*. 2010;5(12):e14235.
16. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. *Bmj*. 2008;336(7646):701-4.

Figures

Figure 1: XR Right Knee (unremarkable)

Figure 2: US Soft Tissue Right Knee (A. Large joint effusion is noted reaching the suprapatellar bursa associated with synovial irregular thickening and hypervascularity for clinical correlation to rule out septic arthritis. B. The largest collection is measuring 8.1 x 2.2cm.)



